Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

7

Revenue 2017

Prevnar 13

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Prevnar 13 was produced by Pfizer.

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win Top-line results from a phase 3 trial of 20-valent candidate PF-06482077 – a follow-up to Pfizer’s 13-valent Prevnar 13 product – showed that the vaccine was safe ... of the franchise in adults, an area where Prevnar 13 has been failing back.

20 for 2020 – Five pharma leaders to watch in 2020

20 for 2020 – Five pharma leaders to watch in 2020 pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia. ... to 2025 built on the Prevnar franchise, rare disease

Shanks v Unilever? Or David v Goliath?

Shanks v Unilever? Or David v Goliath? Moreover, it took Professor Shanks 13 years of expensive litigation to get to this point.

Raising awareness and encouraging support on Rare Disease Day 2020

Raising awareness and encouraging support on Rare Disease Day 2020 Takeda UK, along with 13 rare disease patient groups from across the UK, launched the ‘I am number 17’ campaign to coincide with Rare Disease Day, with the aim to ‘help

Celgene’s Revlimid scores NICE approval in follicular lymphoma

Celgene’s Revlimid scores NICE approval in follicular lymphoma Revlimid plus MabThera demonstrated a median progression-free survival rate of 39.4 months compared to 13.8 months for patients treated with MabThera-placebo.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics